We are international
Donate
TEXT SIZE   


16th Anniversary Gala - October 21, 2006
Sat, Oct 21, 2006

Where:
Regent Beverly Wilshire Hotel
9500 Wilshire Boulevard
Beverly Hills, California 90212




THE VISIONARY AWARD:

  • Dr. Jerome B. Zeldis
    Chief Medical Officer and VP of Medical Affairs
    Celgene Corporation
    Professor of Clinical Medicine
    Robert Wood Johnson Medical School
    USA
  • Jerome Zeldis is Chief Medical Officer and Vice President of Medical Affairs of Celgene Corporation in Warren, NJ. Prior to Celgene, Dr. Zeldis worked at Sandoz Research Institute and Janssen Research Institute in both clinical research and medical development. He has also lent his expertise by serving as a board member for start-up biotechnology companies, currently the Semorex Corporation. Dr. Zeldis attended Brown University for an A.B. and M.S., followed by Yale University for an M.Phil., M.D., and Ph.D. in Molecular Biophysics and Biochemistry (immunochemistry). He trained in Internal Medicine at the UCLA Center for the Health Sciences and in Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. Following his education and training, he became Assistant Professor of Medicine at the Harvard Medical School, Associate Professor of Medicine at University of California, Davis, and Clinical Associate Professor of Medicine at Cornell Medical School. In addition to his roles at Celgene, Dr. Zeldis currently serves as Professor of Clinical Medicine at the Robert Wood Johnson Medical School in New Brunswick, New Jersey.

HONORING THE BANK ON A CURE® TEAM:

  • Dr. Hervé Avet-Loiseau
    Laboratory of Hematology
    University Hospital
    Nantes, France
    IMF Scientific Advisory Board

    Dr. Avet-Loiseau received the IMF's Brian Novis Senior Research Grants in both 2001 and 2002.

  • Dr. Dalsu Baris
    Staff Scientist
    Division of Cancer Epidemiology
    National Cancer Institute (NCI)
    USA
    IMF Scientific Advisory Board

    At the NCI, Dalsu Baris leads an epidemiologic research program focusing on uncovering environmental risk factors for cancer, with particular interest in multiple myeloma. She is currently conducting several epidemiological studies on multiple myeloma, non-Hodgkin's lymphoma and cancer of the urinary bladder. Her many years as a researcher have given to numerous articles published in prestigious journals as a lead investigator covering the health effects of a wide range of environmental exposures, including magnetic and electrical fields, pesticide use, air pollution and the impact of poverty. She also has co-authored 3 book chapters on epidemiology of multiple myeloma. Dr. Baris received her M.D. degree from Hacettepe University in Turkey and earned her Ph.D. degree from McGill University in Canada.

  • Dr. John Crowley
    President & CEO
    Cancer Research And Biostatistics (CRAB)
    USA
    IMF Scientific Advisory Board
  • John Crowley brings three decades of exceptional experience in Biostatistics to his role as President and CEO CRAB, which serves as the Statistical Center for both the Southwest Oncology Group (SWOG) and the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences. Dr. Crowley is one of the first in the country to develop analytical methods and statistical results for microarray-based genomic data on the progression of pre-myeloma to myeloma. Previous to his leadership at CRAB, Dr. Crowley served as Head of the Biostatistics Program at the Fred Hutchinson Cancer Research Center, during which time he was honored with a Mortimer Spiegelman Award, given every year by the American Public Health Association to an outstanding young biostatistician. His credentials also include prestigious fellowships from the American Statistical Association and the American Association for the Advancement of Science. To date he has authored over 225 professional papers and books. Dr. Crowley received his masters and doctorate degrees in Biomathematics from the University of Washington, with a postdoctoral fellow at Stanford University.

  • Dr. Hartmut Goldschmidt
    Autologous Bone Marrow Transplantation Program
    University of Heidelberg
    Germany
    IMF Scientific Advisory Board

    Born and raised in the former East Germany, Hartmut Goldschmidt's early clinical work took place at Charité Medical Center in the former East Berlin. After the fall of the Berlin Wall, Dr. Goldschmidt received a fellowship at University of Heidelberg Medical Center, where, six months later, he established its myeloma program. From 1999 to 2005, Dr. Goldschmidt headed the Autologous Bone Marrow Transplantation Program at University of Heidelberg Hospital. He received the 2003 Paul Martini Prize for excellent achievements in clinical and therapeutic pharmaceutical research.

  • Dr. Gareth Morgan
    Professor of Haematology
    The Royal Marsden Hospital
    United Kingdom
    IMF Board of Directors
    IMF Scientific Advisory Board

    Co-Director of the IMF's Bank On A Cure, Gareth Morgan is a respected clinician and researcher, with a special interest in molecular hematology. Now spearheading the Myeloma Group at The Royal Marsden Hospital, Dr. Morgan was previously affiliated with the University of Leeds. He serves as a journal reviewer for Blood, British Journal of Haematology, Journal of the National Cancer Institute, and Cancer Research and on the Editorial Boards of Leukaemia Research, Clinical Laboratory Haematology, and Haematological Oncology. Dr. Morgan received his medical and haematology specialty training at the Welsh National School of Medicine, the Royal College of Physicians, London, and the Royal College of Pathologists, and received his PhD from the University of London.

  • Dr. Jesús San Miguel
    Head, Department of Hematology
    Hospital Universitario de Salamanca
    Professor of Medicine, Universitario de Salamanca
    Vice Director, Centro de Investigacion del Cancer (CIC)
    Spain
    IMF Scientific Advisory Board

    Jesús San Miguel is Professor of Medicine (Haematology) and Head of the Haematology Department at the University Hospital of Salamanca, Spain, as well as Vice Director of Salamanca's Centro de Investigacion del Cancer and Chairman of the Spanish Myeloma Group. In addition to his role with the IMF's Scientific Advisory Board, Dr. San Miguel is a board member of the Spanish Hematology and Genome Foundations, as well as a member of the editorial board of several scientific journals, including Haematologica (The Hematology Journal). After studying Medicine at the University of Navarra, Spain and completing his residency in Haematology/Internal Medicine at the University Hospital of Salamanca, Dr. San Miguel obtained his PhD and undertook a post-doctoral fellowship at the Leukaemia Unit of Hammersmith Hospital, Royal Postgraduate Medical School, London. In 2003 he organized the IXth International Myeloma Workshop held in Salamanca. He has published over 400 original papers in international journals.

  • Dr. John Shaughnessy
    Associate Professor of Medicine
    University of Arkansas for Medical Sciences
    Director, Lambert Laboratory of Myeloma Genetics
    USA

    John Shaughnessy's work is dedicated to identifying the critical molecular mechanisms and characteristics that affect patient prognosis. Prior to his roles at University of Arkansas, Dr. Shaughnessy was a Research Associate in the Molecular Genetics section of the National Cancer Institute. He received his PhD in Molecular Biology from the University of Maryland and served as a Post-Doctoral Fellow at Mammalian Genetics Laboratory (NCI-Frederick Cancer Research and Development Center, Maryland). His work has been published in Blood, International Journal of Haematology, and the New England Journal of Medicine, among others.

  • Dr. Pieter Sonneveld
    Senior Staff Hematologist
    University Hospital Rotterdam/Dijkzlgt
    Professor of Hematology, Erasmus University, Rotterdam
    The Netherlands
    IMF Scientific Advisory Board

    Through his roles as a researcher, physician and professor, Pieter Sonneveld studies the biological and clinical significance of resistance mechanisms in myeloma and leukemia by cyclosporine and related agents. Previous to his current positions, Dr. Sonneveld spent two years as a researcher at the National Cancer Institute in the USA. Dr. Sonneveld is Chairman of The Netherlands' National Myeloma Group and coordinates the nation's clinical myeloma research. He received his medical degree from Erasmus University in Rotterdam his PhD from University of Leiden.

  • Dr. Brian Van Ness
    Professor & Department Head
    Genetics, Cell Biology and Development
    University of Minnesota
    USA
    IMF Scientific Advisory Board

    Brian Van Ness is Co-Director of the IMF's Bank On A Cure. At the University of Minnesota Cancer Center in Minneapolis, his research focuses on exploring how different genes can influence disease progression and therapeutic response, particularly with regard to multiple myeloma. In addition to his role with the IMF Scientific Advisory Board, Dr. Van Ness serves on the Myeloma Committee of the Eastern Cooperative Oncology Group and is an active member of the American Society of Hematology. In 2000, Dr. Van Ness was part of the NIH Progress Review Group in Lymphoid Malignancies. He has published numerous articles in peer-reviewed journals, including Blood, Cancer Research, Immunology, Journal of Biological Chemistry, Leukemia and Oncogene. Dr. Van Ness received his bachelor's degree in biology and a master's degree in chemistry from Indiana University of Pennsylvania in Indiana, Penn., and his Ph.D. in biochemistry from University of Minnesota.

Purchase tickets online.